<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Corrine K Welt, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William F Crowley, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3190334">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary ovarian insufficiency (POI) is defined as the development of hypergonadotropic hypogonadism before the age of 40 years [
         <a href="#rid1">
          1
         </a>
         ]. The presenting symptoms are similar to those of menopause. In its fully developed form, it is associated with oligomenorrhea or amenorrhea, symptoms of estrogen deficiency, and gonadotropin levels in the menopausal range before age 40 years. POI is distinguished from "induced" POI, ie, POI that is due to early bilateral salpingo-oophorectomy (BSO) or gonadotoxic therapies (chemotherapy and radiotherapy). (See
         <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">
          "Elective oophorectomy or ovarian conservation at the time of hysterectomy"
         </a>
         .)
        </p>
        <p>
         The clinical manifestations and evaluation of women with POI (focusing on women with a normal karyotype) will be reviewed here. The pathogenesis, causes, and management of POI, overviews of autoimmune ovarian insufficiency and Turner syndrome, and the evaluation of diminished ovarian reserve in the setting of female infertility are all discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">
          "Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">
          "Management of primary ovarian insufficiency (premature ovarian failure)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7391.html" rel="external">
          "Clinical manifestations and diagnosis of Turner syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3189171">
         <span class="h1">
          DEFINITIONS AND EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The age-specific incidence of POI is approximately 1 in 250 by age 35 years and 1 in 100 by age 40 years [
         <a href="#rid2">
          2
         </a>
         ]. Natural menopause is defined as the permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of amenorrhea without any other obvious pathological or physiological cause. It occurs at a median age of 51.4 years in normal women. Menopause is a reflection of complete, or near complete, ovarian follicular depletion, with resulting hypoestrogenemia and high follicle-stimulating hormone (FSH) concentrations. Menopause before age 40 years is considered to be abnormal and is referred to as primary ovarian insufficiency (POI). An alternative term, "premature ovarian insufficiency," is used by some experts. (See
         <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">
          "Clinical manifestations and diagnosis of menopause"
         </a>
         .)
        </p>
        <p>
         The terms "premature menopause" and "premature ovarian failure" were used in the past for POI, but both are inaccurate because many patients with POI intermittently produce estrogen and ovulate, a few experience intermittent return of regular menses, and, in 5 to 10 percent of cases, women conceive and have a normal pregnancy [
         <a href="#rid3">
          3
         </a>
         ]. This can occur many years after the diagnosis [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         POI is a spectrum disorder and is a continuum of impaired ovarian function. We define diminished ovarian reserve as impaired ovarian responsiveness to exogenous or endogenous gonadotropin stimulation despite the presence of regular and predictable ovulatory menstrual cycles. Overt POI refers to the presence of irregular menses, elevated serum gonadotropins, and reduced fertility  (
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Diminished ovarian reserve is not synonymous with POI. It is a term used in the context of female infertility evaluation and treatment. The term refers to women over age 40 years who also have abnormal ovarian reserve testing (including low serum anti-müllerian hormone levels), and/or a poor response to ovarian stimulation during in vitro fertilization. (See
         <a class="medical medical_review" href="/z/d/html/111561.html" rel="external">
          "Evaluation and management of infertility in females of advancing age", section on 'Diminished ovarian reserve'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3189178">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary ovarian insufficiency (POI) is characterized by a change in menstrual function (oligomenorrhea and/or amenorrhea), elevated serum gonadotropins and low serum estradiol concentrations, and estrogen deficiency symptoms such as hot flashes and vaginal dryness. However, because intermittent ovarian function occurs in approximately 50 to 75 percent of women with POI [
         <a href="#rid5">
          5-7
         </a>
         ], the absence of vasomotor symptoms or vaginal dryness should not dissuade one from considering the diagnosis of POI in a woman who presents with menstrual irregularity  (
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3873476397">
         <span class="h2">
          Change in menstrual cycles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many women present because of irregular menstrual cycles; others may first present because of difficulty conceiving  (
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ). Some may also present with primary amenorrhea.
        </p>
        <p>
         Most women who develop 46,XX POI have experienced normal puberty and have established regular menses prior to the development of the condition [
         <a href="#rid8">
          8
         </a>
         ]. A disturbance in menstrual pattern is the most common presenting symptom, but there is no characteristic menstrual history that heralds the onset of 46,XX POI [
         <a href="#rid9">
          9
         </a>
         ]. Patients may develop amenorrhea acutely or experience a prolonged prodrome of oligomenorrhea.
        </p>
        <p>
         POI sometimes first becomes apparent when menstruation fails to return after stopping oral contraceptives (OCs) or following a pregnancy. The OC in this instance has masked most of the characteristic features of POI, including the change in menstrual cycles, hot flashes, and increase in serum gonadotropins, so the individual is unaware that there is a problem until she stops the pill.
        </p>
        <p class="headingAnchor" id="H897793056">
         <span class="h2">
          Consequences of estrogen deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of exogenous estrogen replacement, women with POI are at an increased risk for a number of symptoms and comorbidities.
        </p>
        <p class="headingAnchor" id="H2243359989">
         <span class="h3">
          Hot flashes
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some women, vasomotor symptoms may begin before the development of abnormal menstrual cycles; they tend to occur just prior to menses when estrogen levels are lowest. In addition, some women taking OCs experience vasomotor symptoms during the placebo or pill-free part of the cycle [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">
          "Menopausal hot flashes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3131884615">
         <span class="h3">
          Vaginal dryness
         </span>
         <span class="headingEndMark">
          —
         </span>
         With progression to amenorrhea and profound estrogen deficiency, symptoms of atrophic vaginitis and dyspareunia eventually become prominent (if estrogen is not replaced). (See
         <a class="medical medical_review" href="/z/d/html/5464.html" rel="external">
          "Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1111097695">
         <span class="h3">
          Bone loss and osteoporosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         POI is an important risk factor for bone loss and osteoporosis [
         <a href="#rid10">
          10-12
         </a>
         ], especially in young women who develop ovarian dysfunction before they achieve peak adult bone mass [
         <a href="#rid13">
          13
         </a>
         ]. Women with POI also have a higher incidence of osteoporotic fractures [
         <a href="#rid14">
          14
         </a>
         ] (see
         <a class="local">
          'Assess bone mineral density with DXA'
         </a>
         below). The approach to managing bone health in women with POI is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">
          "Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'
         </a>
         .)
        </p>
        <p>
         In a large, cross-sectional study of young women with 46,XX POI as compared with control women, patients on average had 2 to 3 percent lower bone density in the lumbar spine, femoral neck, and total hip [
         <a href="#rid15">
          15
         </a>
         ]. Approximately 50 percent of women with 46,XX POI had evidence of vitamin D deficiency as well as inadequate calcium intake, and 25 percent had no regular exercise program [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3061958651">
         <span class="h3">
          Cardiovascular morbidity and mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         POI is associated with increased cardiovascular morbidity and mortality, possibly related to endothelial dysfunction [
         <a href="#rid16">
          16-22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1468.html" rel="external">
          "Overview of atherosclerotic cardiovascular risk factors in females", section on 'Early menopause'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1468.html" rel="external">
          "Overview of atherosclerotic cardiovascular risk factors in females", section on 'Other conditions associated with cardiovascular disease risk'
         </a>
         .)
        </p>
        <p>
         Observational data suggest that early menopause may be associated with small increases in total mortality and mortality due to ischemic heart disease [
         <a href="#rid19">
          19,23-25
         </a>
         ] and also possibly ischemic stroke [
         <a href="#rid26">
          26
         </a>
         ]. However, at this time, evidence is insufficient to recommend hormone replacement therapy for the sole purpose of preventing cardiovascular disease or stroke.
        </p>
        <p class="headingAnchor" id="H591129656">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other potential consequences of estrogen deficiency include diminished sexual well-being [
         <a href="#rid27">
          27-29
         </a>
         ].
        </p>
        <p>
         Some studies suggest that women under age 43 years who undergo bilateral oophorectomy and do not receive estrogen replacement are at increased risk for dementia and cognitive decline [
         <a href="#rid30">
          30
         </a>
         ]. This has also been demonstrated for women with POI [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">
          "Elective oophorectomy or ovarian conservation at the time of hysterectomy", section on 'Cognitive function and neurologic disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3973761571">
         <span class="h2">
          Emotional health
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of POI is emotionally traumatic for most women because it disrupts their life plans, hopes, and dreams with regard to raising a family. Women with POI may develop related depression and anxiety disorders [
         <a href="#rid32">
          32,33
         </a>
         ]. Data suggest that depression frequently occurs after the onset of menstrual irregularity but often precedes the diagnosis of POI [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         As compared with controls, women with 46,XX POI score adversely in the domains of physical and emotional health on the World Health Organization Quality of Life (WHOQOL)-BREF instrument [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         In one report, women with 46,XX POI (n = 100) had higher scores on depression, anxiety, and negative affect scales when compared with a group of control women (n = 60) [
         <a href="#rid36">
          36
         </a>
         ]. On regression analysis, factors that contributed significantly to these symptoms were illness uncertainty and stigma associated with the diagnosis. This diagnosis disrupts life plans and introduces symptoms of grief, anxiety, and depression. When the condition develops during adolescence, it is important to take a family systems approach to the evaluation [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3189199">
         <span class="h2">
          Physical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most women with 46,XX POI have experienced normal pubertal development and menarche and have no abnormalities on physical examination, but occasionally, the following may be found:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of Hashimoto's thyroiditis or Graves' disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased skin pigmentation or vitiligo related to autoimmune primary adrenal insufficiency. In this case, orthostatic hypotension may also be present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs of atrophic vaginitis may be seen, although normal vaginal examination including normal cervical mucus and vaginal maturation index may also be seen if there has been recent ovarian function [
         <a href="#rid5">
          5,6,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ovarian enlargement related to autoimmune lymphocytic oophoritis or a steroidogenic enzyme defect [
         <a href="#rid39">
          39,40
         </a>
         ]. This may also be noted on pelvic ultrasound.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ptosis, which has been associated with a rare familial form of POI (blepharophimosis/ptosis/epicanthus inversus syndrome [BPES]) [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">
          "Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)", section on 'Other rare syndromic defects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Features of Turner syndrome, which are reviewed in detail separately, include short stature, low posterior hairline, high arched palate, shield chest with widely spaced nipples, a wide carrying angle, and short fourth and fifth metacarpals. (See
         <a class="medical medical_review" href="/z/d/html/7391.html" rel="external">
          "Clinical manifestations and diagnosis of Turner syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H763309">
         <span class="h2">
          Biochemical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The typical biochemical features of POI include low serum estradiol and elevated serum follicle-stimulating hormone (FSH) concentrations, similar to what is seen in normal menopause. However, as noted, many women have intermittent ovarian function, so normal laboratory findings may be seen in women who are having ovulatory menstrual cycles  (
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1222514109">
         <span class="h2">
          Transvaginal ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antral follicles that appear to be endocrinologically active have been detected by transvaginal ultrasound examination in nearly 75 percent of women with 46,XX POI [
         <a href="#rid5">
          5-7
         </a>
         ]. Autoimmune oophoritis may also be associated with the development of large, luteinized follicle cysts; the characteristic ultrasound appearance is enlarged cystic ovaries [
         <a href="#rid39">
          39,40,42-46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H811668192">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H974031151">
         <span class="h2">
          Primary ovarian insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary ovarian insufficiency is a life-altering diagnosis. The diagnosis of primary ovarian insufficiency (POI) can be made definitively in women younger than 40 years with irregular menses in association with follicle-stimulating hormone (FSH) concentrations in the postmenopausal range (as defined by the measuring laboratory). The presence of amenorrhea is not required to make the diagnosis, as women frequently have intermittent ovarian function and spontaneous menses [
         <a href="#rid5">
          5,6,8
         </a>
         ], even years after their initial presentation  (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Measurement of serum FSH can be misleading in women with POI who still have intermittent ovarian function as it can be in the normal range during ovulatory cycles but in the postmenopausal range when experiencing oligo- or amenorrhea. If one suspects POI, we suggest measuring FSH on cycle day 3 in women with menstrual cycles; for women with amenorrhea, the sample can be drawn on a random day. If estradiol drawn on the same day is elevated &gt;100 pg/mL, the FSH may be suppressed and indeterminate even in a patient with amenorrhea, owing to occasional follicle development that can occur.
        </p>
        <p>
         The presence of hot flashes and/or vaginal dryness is suggestive of POI as these symptoms are uncommon in women with menstrual disturbances due to other causes. The absence of these symptoms does not rule out the possibility for the reasons mentioned above; many women have intermittent ovarian function with follicular development, estrogen secretion, and intermittently may have normal regular menses. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         The progestin-withdrawal test is no substitute for laboratory evaluation, because intermittent estradiol production can result in withdrawal bleeding but does not negate the diagnosis [
         <a href="#rid8">
          8
         </a>
         ]  (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">
          "Evaluation and management of secondary amenorrhea", section on 'Assessment of estrogen status'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H742074547">
         <span class="h2">
          Diminished ovarian reserve
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of diminished ovarian reserve in the setting of infertility is reviewed in detail separately. In addition to day 3 FSH and estradiol measurements, measurement of serum anti-müllerian hormone concentration and antral follicle count (on transvaginal ultrasound) have been used. In most assays, an FSH measured on cycle day 3 that is &gt;10 to 15 international units/L, with a simultaneous serum estradiol ≥80 pg/mL (294 pmol/L), is suggestive of lower fertility and diminished ovarian reserve POI  (
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Definitions and epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5445.html" rel="external">
          "Female infertility: Evaluation", section on 'Assessment of ovarian reserve'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1222516137">
         <span class="h2">
          Importance of early diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the fact that early diagnosis of POI is important for osteoporosis prevention (and possibly prevention of later coronary heart disease), many women experience a significant delay in diagnosis after the onset of a disordered menstrual pattern (as long as a five-year delay in 25 percent of women) [
         <a href="#rid9">
          9
         </a>
         ]. In addition, over 50 percent of young women with POI have reported seeing three or more clinicians before laboratory testing was finally done [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Young women who experience menstrual irregularity for three or more consecutive months deserve evaluation at their first visit [
         <a href="#rid47">
          47
         </a>
         ]. The presence of regular and predictable menstrual cycles is an indication that the hypothalamic-pituitary-ovarian axis is functioning properly. Loss of menstrual regularity may be a sign of ovarian insufficiency and the associated estrogen deficiency. (See
         <a class="medical medical_review" href="/z/d/html/7403.html" rel="external">
          "Evaluation and management of primary amenorrhea"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">
          "Evaluation and management of secondary amenorrhea"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2784913038">
         <span class="h2">
          Informing the patient of the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important steps after making the diagnosis of primary ovarian insufficiency (POI)  (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         ) are to inform the patient of the diagnosis in a sensitive and caring manner, provide accurate information, and offer referral to appropriate resources for emotional support. This issue is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">
          "Management of primary ovarian insufficiency (premature ovarian failure)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H119845173">
         <span class="h1">
          EVALUATION TO EXCLUDE OTHER DISORDERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other tests that should be done to rule out other causes of menstrual cycle dysfunction include  (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">
          "Evaluation and management of secondary amenorrhea", section on 'Laboratory testing'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pregnancy test, which should be performed in any woman of childbearing age who has missed menses
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum prolactin concentration, to determine if hyperprolactinemia is the cause of the symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid-stimulating hormone (TSH) to determine whether thyroid disease is present, as thyroid disease can cause irregular menses and is more common in primary ovarian insufficiency (POI)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H119845181">
         <span class="h1">
          ADDITIONAL EVALUATION ONCE DIAGNOSIS IS MADE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the diagnosis of primary ovarian insufficiency (POI) is made, other evaluation should be performed to determine the underlying cause of the POI and to evaluate for the presence of coexisting disorders. The underlying cause has been considered to be unknown or "idiopathic" in up to 70 percent of women with POI. However, whole exome or whole genome sequencing studies have identified the cause of POI in approximately 30 to 35 percent of patients [
         <a href="#rid48">
          48-50
         </a>
         ]. We do not suggest routine genetic testing at this time, although it is becoming more useful as the number of genes increases. (See
         <a class="local">
          'Genetic testing'
         </a>
         below.)
        </p>
        <p>
         Our approach to evaluating patients is consistent with that of the American College of Obstetricians and Gynecologists [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H275085718">
         <span class="h2">
          Clues to underlying etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The medical history from a woman with possible POI may provide clues about the underlying etiology:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior ovarian surgery, chemotherapy, or radiation therapy, as these all may damage ovarian tissue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of anorexia, weight loss, vague abdominal pain, weakness, fatigue, salt craving, or increased skin pigmentation that suggest the presence of primary adrenal insufficiency. Approximately 3 percent of women with POI develop adrenal insufficiency, a 300-fold increase compared with the general population [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A personal or family history of autoimmune diseases, either alone or in combination, that might suggest polyglandular autoimmune syndromes, such as hypothyroidism or Graves' disease, primary adrenal insufficiency, vitiligo, myasthenia gravis, hypoparathyroidism, recurrent mucocutaneous candidiasis, or type 1 diabetes. Celiac disease should also be considered. Autoimmune oophoritis may occur as part of type I or type II syndromes of polyglandular autoimmune syndrome. In one study of 457 women with POI, 15 percent had chronic lymphocytic thyroiditis, compared with a prevalence of 5.8 percent in the United States population of women [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Polyglandular autoimmune syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A family history of POI, because approximately 10 percent of cases are familial [
         <a href="#rid54">
          54
         </a>
         ]. A family history of POI raises concern for a fragile X premutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A family history of fragile X syndrome, intellectual disability, developmental delay, Parkinsonism, intension tremor, ataxia, or dementia, because approximately 6 percent of cases of POI are associated with premutations in the fragile X messenger ribonucleoprotein 1 (
         <em>
          FMR1
         </em>
         ) gene (the gene responsible for the fragile X syndrome and the fragile X-associated tremor/ataxia syndrome) [
         <a href="#rid55">
          55,56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">
          "Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)", section on 'Fragile X syndrome premutation carriers'
         </a>
         and
         <a class="local">
          'Test for FMR1 premutation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/437.html" rel="external">
          "Fragile X syndrome: Prenatal screening and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Association with deafness, because familial autosomal recessive POI may be associated with deafness as part of Perrault syndrome [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3189220">
         <span class="h2">
          Test for adrenal autoantibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Young women with POI are at increased risk for developing autoimmune adrenal insufficiency, a potentially fatal disorder [
         <a href="#rid59">
          59
         </a>
         ]. Generally, the development of disordered menses associated with POI precedes the development of symptomatic adrenal insufficiency by several years [
         <a href="#rid60">
          60
         </a>
         ]. If proper screening is performed, approximately 3 percent of women with POI will be found to have asymptomatic autoimmune adrenal insufficiency [
         <a href="#rid52">
          52,61
         </a>
         ].
        </p>
        <p>
         As a screen for the presence of asymptomatic autoimmune adrenal insufficiency, serum adrenal cortical and 21-hydroxylase antibodies should be measured in all women at the time of diagnosis of 46,XX POI. Women with adrenal autoimmunity detected by the presence of autoantibodies have a 50 percent risk of developing adrenal insufficiency [
         <a href="#rid62">
          62
         </a>
         ]. These women should then be evaluated for the presence of adrenal insufficiency by an 8 AM serum cortisol and plasma corticotropin (ACTH).
        </p>
        <p>
         Testing for 21-hydroxylase antibodies may serve the dual purpose of screening for autoimmune adrenal insufficiency and making the diagnosis of autoimmune oophoritis. However, in rare cases, 21-hydroxylase antibodies may be negative despite a positive adrenal cortical test determined by indirect immunofluorescence (due to the presence of antibodies to other steroidogenic enzymes such as 17-hydroxylase or side-chain cleavage) [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         Even if adrenal function is found to be normal at initial evaluation, women with positive adrenal cortical antibodies should be followed annually by these tests. Monitoring for women with negative antibodies is reviewed separately.
        </p>
        <p>
         Further evaluation and management of these patients and the diagnosis of adrenal insufficiency are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1222515203">
         <span class="h2">
          Other autoimmune evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Young women with POI are also at increased risk of autoimmune hypothyroidism and should be screened for this condition [
         <a href="#rid63">
          63
         </a>
         ]. Testing should therefore include thyroid-stimulating hormone (TSH) and thyroid-peroxidase autoantibodies. Other disorders associated with autoimmune polyglandular syndrome are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'Autoimmune adrenalitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">
          "Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Thyroid peroxidase antibodies'
         </a>
         .)
        </p>
        <p>
         Ovarian biopsy to detect autoimmune oophoritis is not recommended [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7414.html" rel="external">
          "Autoimmune primary ovarian insufficiency (premature ovarian failure)", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3189227">
         <span class="h2">
          Karyotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         A karyotype should be performed as part of the basic evaluation for all patients with POI, with or without stigmata of Turner syndrome. Neither age of onset nor prior parity rules out a chromosomal abnormality. Overall, in patients who have experienced normal puberty before developing POI, an abnormal karyotype will explain the disorder in a low percentage of cases [
         <a href="#rid8">
          8
         </a>
         ]. Women with X chromosome abnormalities have developed POI after having previously delivered normal children [
         <a href="#rid65">
          65
         </a>
         ]. Identification of a chromosomal abnormality alters management, and thus, this test should be part of the standard evaluation. Women with Turner syndrome should be screened for associated abnormalities. (See
         <a class="medical medical_review" href="/z/d/html/7391.html" rel="external">
          "Clinical manifestations and diagnosis of Turner syndrome"
         </a>
         .)
        </p>
        <p>
         Although rare in women with POI, those with Y chromosome material present require oophorectomy because of the risk of gonadal tumors in women with Y chromosome-containing gonadal tissue. Molecular genetic techniques to identify the critical Y chromosome components have been developed [
         <a href="#rid66">
          66,67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7391.html" rel="external">
          "Clinical manifestations and diagnosis of Turner syndrome", section on 'Risk of malignancy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3189234">
         <span class="h2">
          Test for FMR1 premutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with several professional organizations and suggest that women with overt and biochemical POI undergo testing for a premutation in
         <em>
          FMR1
         </em>
         [
         <a href="#rid68">
          68-70
         </a>
         ]. There is an established association between POI and premutation in the
         <em>
          FMR1
         </em>
         gene, the gene responsible for fragile X syndrome [
         <a href="#rid71">
          71
         </a>
         ]. Fragile X syndrome is an X-linked disorder that is the most common cause of heritable intellectual disability. (See
         <a class="medical medical_review" href="/z/d/html/2924.html" rel="external">
          "Fragile X syndrome: Clinical features and diagnosis in children and adolescents"
         </a>
         .)
        </p>
        <p>
         In cases of familial POI, approximately 14 percent will be found to have a premutation in the
         <em>
          FMR1
         </em>
         gene. In sporadic cases, the prevalence of this premutation is approximately 2 percent [
         <a href="#rid72">
          72,73
         </a>
         ].
        </p>
        <p>
         The
         <em>
          FMR1
         </em>
         premutation as a mechanism of POI is associated with a clinical spectrum of impaired ovarian function  (
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ). This involves a continuum from: diminished ovarian reserve as detected by a low response to gonadotropin stimulation in the context of infertility treatment, diminished ovarian reserve as detected by an elevated basal follicle-stimulating hormone (FSH) level (biochemical), and overt POI that is associated with disruption of the menstrual cycle [
         <a href="#rid1">
          1,74,75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2852284561">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to 70 percent of women with POI have been considered to have idiopathic or "unexplained" POI. However, studies using whole exome or whole genome sequencing have identified genetic variants in approximately 30 to 35 percent of patients with POI [
         <a href="#rid48">
          48
         </a>
         ]. In a prospective cohort study of 269 well-phenotyped women with POI screened for variants of 18 known POI genes by next-generation sequencing, 102 (38 percent) were identified as having at least one genetic abnormality [
         <a href="#rid49">
          49
         </a>
         ]. Another study examining targeting 88 POI risk genes identified a genetic cause in 29 percent [
         <a href="#rid50">
          50
         </a>
         ]. Given the increasing number of identified genetic variants in women with POI, routine genetic testing may soon be part of the clinical work-up.
        </p>
        <p class="headingAnchor" id="H3189248">
         <span class="h2">
          Assess bone mineral density with DXA
         </span>
         <span class="headingEndMark">
          —
         </span>
         POI is an important risk factor for bone loss and osteoporosis [
         <a href="#rid10">
          10-12
         </a>
         ]. Therefore, at the time of diagnosis, a bone density test (dual-energy x-ray absorptiometry [DXA]) should be obtained. (See
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">
          "Overview of dual-energy x-ray absorptiometry"
         </a>
         .)
        </p>
        <p>
         Women with POI have a higher incidence of osteoporotic fractures, largely because of estrogen deficiency [
         <a href="#rid14">
          14
         </a>
         ]. The approach to managing bone health in women with POI is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">
          "Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1222516394">
         <span class="h1">
          FOLLOW-UP AFTER DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many important issues to consider in the follow-up and management of women with a diagnosis of primary ovarian insufficiency (POI), including emotional health, fertility, sexual function, bone health, cardiovascular health, and the risk for developing primary adrenal insufficiency (in women with autoimmune oophoritis). Our approach is consistent with that of the American College of Obstetricians and Gynecologists [
         <a href="#rid51">
          51
         </a>
         ]. All of these issues are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">
          "Management of primary ovarian insufficiency (premature ovarian failure)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H490757068">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113774.html" rel="external">
          "Society guideline links: Primary ovarian insufficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3189112">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15606.html" rel="external">
          "Patient education: Primary ovarian insufficiency (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2176.html" rel="external">
          "Patient education: Primary ovarian insufficiency (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3189119">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and epidemiology
         </strong>
         – Primary (or premature) ovarian insufficiency (POI, formerly referred to as premature ovarian failure) is one of many causes that may be found when evaluating a woman for amenorrhea or oligomenorrhea. The age-specific incidence of POI is approximately 1 in 250 by age 35 years and 1 in 100 by age 40 years. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – POI is characterized by a change in menstrual function (oligomenorrhea and eventual amenorrhea), elevated serum gonadotropin and low serum estradiol concentrations, and estrogen deficiency symptoms such as hot flashes and vaginal dryness. However, because intermittent ovarian function occurs in approximately 50 to 75 percent of women with POI, the absence of vasomotor symptoms or vaginal dryness should not dissuade one from considering the diagnosis of POI in a woman who presents with menstrual irregularity  (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef93158" href="/z/d/graphic/93158.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of POI can be made definitively in women younger than 40 years with irregular menses in association with follicle-stimulating hormone (FSH) concentrations in the menopausal range levels, as defined by the testing laboratory  (
         <a class="graphic graphic_algorithm graphicRef131982" href="/z/d/graphic/131982.html" rel="external">
          algorithm 1
         </a>
         ). The presence of amenorrhea is not required to make the diagnosis, as women frequently have intermittent ovarian function and spontaneous menses even years after their initial presentation. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The diagnosis of POI is emotionally traumatic for most women as it disrupts their life plans, hopes, and dreams with regard to fertility. Anxiety and/or depression are both common in women with POI. (See
         <a class="local">
          'Emotional health'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diagnosis is important in order to explain to the patient the variable natural history of the condition, to look for associated diseases, and, most importantly, to treat the hypogonadism. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional evaluation
         </strong>
         – After the diagnosis of POI is made, other evaluation should be performed to determine the underlying cause of the POI and to evaluate for the presence of coexisting disorders. (See
         <a class="local">
          'Additional evaluation once diagnosis is made'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H239523625">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Lawrence M Nelson, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowchock FS, McCabe JL, Montgomery BB. Pregnancy after corticosteroid administration in premature ovarian failure (polyglandular endocrinopathy syndrome). Am J Obstet Gynecol 1988; 158:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson LM, Anasti JN, Kimzey LM, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994; 79:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor AE, Adams JM, Mulder JE, et al. A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab 1996; 81:3615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubayter ZR, Popat V, Vanderhoof VH, et al. A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril 2010; 94:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990; 53:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alzubaidi NH, Chapin HL, Vanderhoof VH, et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002; 99:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pouillès JM, Trémollières F, Bonneu M, Ribot C. Influence of early age at menopause on vertebral bone mass. J Bone Miner Res 1994; 9:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leite-Silva P, Bedone A, Pinto-Neto AM, et al. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure. Arch Gynecol Obstet 2009; 280:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anasti JN, Kalantaridou SN, Kimzey LM, et al. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998; 91:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause 2007; 14:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 2009; 94:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009; 113:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89:3907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 2005; 111:1462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostberg JE, Storry C, Donald AE, et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf) 2007; 66:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA 2019; 322:2411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blümel JE, Mezones-Holguín E, Chedraui P, et al. Is premature ovarian insufficiency associated with mortality? A three-decade follow-up cohort. Maturitas 2022; 163:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999; 52:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Kleijn MJ, van der Schouw YT, Verbeek AL, et al. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002; 155:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocca WA, Grossardt BR, Miller VM, et al. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012; 19:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalantaridou SN, Vanderhoof VH, Calis KA, et al. Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. Fertil Steril 2008; 90:1805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008; 15:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011; 18:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan J, Scali J, Carrière I, et al. Impact of a premature menopause on cognitive function in later life. BJOG 2014; 121:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groff AA, Covington SN, Halverson LR, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril 2005; 83:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orshan SA, Furniss KK, Forst C, Santoro N. The lived experience of premature ovarian failure. J Obstet Gynecol Neonatal Nurs 2001; 30:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt PJ, Luff JA, Haq NA, et al. Depression in women with spontaneous 46, XX primary ovarian insufficiency. J Clin Endocrinol Metab 2011; 96:E278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benetti-Pinto CL, de Almeida DM, Makuch MY. Quality of life in women with premature ovarian failure. Gynecol Endocrinol 2011; 27:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis M, Ventura JL, Wieners M, et al. The psychosocial transition associated with spontaneous 46,XX primary ovarian insufficiency: illness uncertainty, stigma, goal flexibility, and purpose in life as factors in emotional health. Fertil Steril 2010; 93:2321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Covington SN, Hillard PJ, Sterling EW, et al. A family systems approach to primary ovarian insufficiency. J Pediatr Adolesc Gynecol 2011; 24:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann E, Singer D, Pitkin J, et al. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric 2012; 15:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biscotti CV, Hart WR, Lucas JG. Cystic ovarian enlargement resulting from autoimmune oophoritis. Obstet Gynecol 1989; 74:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larrea F, Lisker R, Bañuelos R, et al. Hypergonadotrophic hypogonadism in an XX female subject due to 17,20 steroid desmolase deficiency. Acta Endocrinol (Copenh) 1983; 103:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bannatyne P, Russell P, Shearman RP. Autoimmune oophoritis: a clinicopathologic assessment of 12 cases. Int J Gynecol Pathol 1990; 9:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burrell LM, Murdoch A, Angus B, White MC. Autoimmune ovarian failure with elevated serum levels of luteinizing hormone and enlarged ovaries. Case report. Br J Obstet Gynaecol 1990; 97:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonsdale RN, Roberts PF, Trowell JE. Autoimmune oophoritis associated with polycystic ovaries. Histopathology 1991; 19:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welt CK, Hall JE, Adams JM, Taylor AE. Relationship of estradiol and inhibin to the follicle-stimulating hormone variability in hypergonadotropic hypogonadism or premature ovarian failure. J Clin Endocrinol Metab 2005; 90:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welt CK, Falorni A, Taylor AE, et al. Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels. J Clin Endocrinol Metab 2005; 90:3069.
          </a>
         </li>
         <li class="breakAll">
          Mishell DRJ, Stenchever MA, Droegemueller W, Herbst AL. Primary and Secondary Amenorrhea. In: Comprehensive Gynecology, 3rd ed, Mosby, St. Louis 1997. p.1043.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker EJ, Grover SR, Bachelot A, et al. Premature Ovarian Insufficiency: New Perspectives on Genetic Cause and Phenotypic Spectrum. Endocr Rev 2016; 37:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskenazi S, Bachelot A, Hugon-Rodin J, et al. Next Generation Sequencing Should Be Proposed to Every Woman With "Idiopathic" Primary Ovarian Insufficiency. J Endocr Soc 2021; 5:bvab032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heddar A, Ogur C, Da Costa S, et al. Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine. EBioMedicine 2022; 84:104246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol 2014; 124:193. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakalov VK, Vanderhoof VH, Bondy CA, Nelson LM. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 2002; 17:2096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakalov VK, Gutin L, Cheng CM, et al. Autoimmune disorders in women with turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun 2012; 38:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kasteren YM, Hundscheid RD, Smits AP, et al. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod 1999; 14:2455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marozzi A, Vegetti W, Manfredini E, et al. Association between idiopathic premature ovarian failure and fragile X premutation. Hum Reprod 2000; 15:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishi Y, Hamamoto K, Kajiyama M, Kawamura I. The Perrault syndrome: clinical report and review. Am J Med Genet 1988; 31:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers CM, Boughman JA, Rivas M, et al. Gonadal (ovarian) dysgenesis in 46,XX individuals: frequency of the autosomal recessive form. Am J Med Genet 1996; 63:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Rossi A, Dalla Pria S, et al. Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol (Oxf) 1993; 39:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turkington RW, Lebovitz HE. Extra-adrenal endocrine deficiencies in Addison's disease. Am J Med 1967; 43:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2005; 84:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Volpato M, Rees Smith B, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim TJ, Anasti JN, Flack MR, et al. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1997; 89:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khastgir G, Abdalla H, Studd JW. The case against ovarian biopsy for the diagnosis of premature menopause. Br J Obstet Gynaecol 1994; 101:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krauss CM, Turksoy RN, Atkins L, et al. Familial premature ovarian failure due to an interstitial deletion of the long arm of the X chromosome. N Engl J Med 1987; 317:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gemmill RM, Pearce-Birge L, Bixenman H, et al. Y chromosome--specific DNA sequences in Turner-syndrome mosaicism. Am J Hum Genet 1987; 41:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tho SP, McDonough PG. Use of Y DNA probes to identify children at risk for dysgenetic gonadal tumors. Clin Obstet Gynecol 1987; 30:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists Committee on Genetics. ACOG committee opinion. No. 338: Screening for fragile X syndrome. Obstet Gynecol 2006; 107:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McConkie-Rosell A, Finucane B, Cronister A, et al. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005; 14:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steril 2007; 87:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000; 97:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conway GS, Hettiarachchi S, Murray A, Jacobs PA. Fragile X premutations in familial premature ovarian failure. Lancet 1995; 346:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welt CK, Smith PC, Taylor AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab 2004; 89:4569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Caro JJ, Dominguez C, Sherman SL. Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile x-associated primary ovarian insufficiency. Ann N Y Acad Sci 2008; 1135:99.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7443 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19196677" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical practice. Primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3960433" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Incidence of premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10582785" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3337157" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pregnancy after corticosteroid administration in premature ovarian failure (polyglandular endocrinopathy syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962345" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8855811" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19939372" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2110072" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical features of young women with hypergonadotropic amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11978278" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8191923" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Influence of early age at menopause on vertebral bone mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19104824" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20708256" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9464713" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Bone loss in young women with karyotypically normal spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17476146" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Effect of early menopause on bone mineral density and fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19401379" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bone mineral density in estrogen-deficient young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16645540" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384117" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15292326" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16221806" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Age at natural menopause and cause-specific mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781742" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17371475" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31738818" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35752062" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Is premature ovarian insufficiency associated with mortality? A three-decade follow-up cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10235170" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836198" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21993082" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Premature menopause or early menopause and risk of ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17961560" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18257141" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21127440" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sexual function of women with premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761551" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24802975" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Impact of a premature menopause on cognitive function in later life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15950644" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Assessing the emotional needs of women with spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11308110" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The lived experience of premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21047929" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Depression in women with spontaneous 46, XX primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21214499" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Quality of life in women with premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19243752" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The psychosocial transition associated with spontaneous 46,XX primary ovarian insufficiency: illness uncertainty, stigma, goal flexibility, and purpose in life as factors in emotional health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21269850" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A family systems approach to primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22335389" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Psychosocial adjustment in women with premature menopause: a cross-sectional survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2761940" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cystic ovarian enlargement resulting from autoimmune oophoritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6308936" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Hypergonadotrophic hypogonadism in an XX female subject due to 17,20 steroid desmolase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11175783" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2373586" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Autoimmune oophoritis: a clinicopathologic assessment of 12 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2340260" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Autoimmune ovarian failure with elevated serum levels of luteinizing hormone and enlarged ovaries. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1916689" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Autoimmune oophoritis associated with polycystic ovaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15562017" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Relationship of estradiol and inhibin to the follicle-stimulating hormone variability in hypergonadotropic hypogonadism or premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705922" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705922" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27690531" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Premature Ovarian Insufficiency: New Perspectives on Genetic Cause and Phenotypic Spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34095689" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Next Generation Sequencing Should Be Proposed to Every Woman With "Idiopathic" Primary Ovarian Insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36099812" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24945456" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151443" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22342295" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Autoimmune disorders in women with turner syndrome and women with karyotypically normal primary ovarian insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10527968" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10611212" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Association between idiopathic premature ovarian failure and fragile X premutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15065016" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3067578" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The Perrault syndrome: clinical report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8826428" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Gonadal (ovarian) dysgenesis in 46,XX individuals: frequency of the autosomal recessive form.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8348706" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Premature ovarian failure: autoimmunity and natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4168683" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Extra-adrenal endocrine deficiencies in Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16213850" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9062509" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9166320" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8305405" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The case against ovarian biopsy for the diagnosis of premature menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3600701" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Familial premature ovarian failure due to an interstitial deletion of the long arm of the X chromosome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3475977" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Y chromosome--specific DNA sequences in Turner-syndrome mosaicism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3308256" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Use of Y DNA probes to identify children at risk for dysgenetic gonadal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16738187" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : ACOG committee opinion. No. 338: Screening for fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16247297" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Fragile X syndrome: diagnostic and carrier testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16047089" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17074338" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The FMR1 premutation and reproduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11449487" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Premature ovarian failure in the fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7630263" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Fragile X premutations in familial premature ovarian failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356064" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Evidence of early ovarian aging in fragile X premutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574214" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile x-associated primary ovarian insufficiency.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
